Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer.
Neoadjuvant chemotherapy has become common practice in the management of patients with non-metastatic pancreatic adenocarcinoma. This strategy helps better select patients who would benefit from surgical resection and also increase the number of patients amenable to surgical resection whose tumor seemed too locally advanced on initial imaging. However, several studies have shown that the radiological evaluation of the response after neoadjuvant therapy is difficult for pancreatic carcinoma. This article reviews the scientific basis of neoadjuvant therapy for non-metastatic pancreatic cancer and provides an update on tumor response evaluation with imaging after neoadjuvant treatment.
Department of Diagnostic and Interventional Imaging, Hôpital du Haut-Lévèque, University Hospital of Bordeaux, Pessac, France. Electronic address: cassinotto@gmail.com.
C
C
Cassinotto
Department of Hepatobilliary Surgery and Liver Transplantation, Centre Hépatobiliaire, Hôpital Paul-Brousse, Villejuif, France.
A
A
Sa-Cunha
Department of Diagnostic and Interventional Imaging, Hôpital du Haut-Lévèque, University Hospital of Bordeaux, Pessac, France.
H
H
Trillaud
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D061330:Multidetector Computed Tomography; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D011379:Prognosis
D000970:Antineoplastic Agents
Cancer classification; Imaging techniques; Neoadjuvant therapy; Pancreatic cancer; Response to treatment